Review
Nutrition & Dietetics
Matteo Nadile, Maria Ilektra Retsidou, Katerina Gioti, Apostolos Beloukas, Evangelia Tsiani
Summary: Cervical cancer is a global health concern, with a high number of cases and deaths each year. Resveratrol, a natural substance found in plants, has shown potential anticancer properties. Studies have found that resveratrol can inhibit proliferation, induce cell cycle arrest, and promote apoptosis in cervical cancer cells. It can also reduce the expression of HPV oncoproteins and increase the levels of tumor suppressor p53. In vivo studies on mice have shown a reduction in tumor volume and weight with resveratrol treatment. Overall, resveratrol has the ability to target certain signaling molecules involved in cervical cancer cell proliferation and survival. Further research is needed to fully understand its potential in cervical cancer treatment.
Article
Cell Biology
Xuhui Fan, Haotian Fu, Ni Xie, Hangcheng Guo, Tiantian Fu, Yunfeng Shan
Summary: The study revealed that panaxadiol significantly inhibited proliferation and induced apoptosis in human pancreatic cancer cells, as well as suppressed the migration of pancreatic cancer cells, suggesting its potential as an anti-tumor agent for pancreatic cancer treatment.
Review
Biochemistry & Molecular Biology
Katarzyna Ratajczak, Sylwia Borska
Summary: Cancer diseases pose a major challenge in clinical medicine globally, with drug resistance being a significant issue. Natural compounds, particularly polyphenols, are believed to have pleiotropic effects on cells and toxic effects on cancer cells, showing promise as a new approach to cancer treatment. Studies on the effectiveness of resveratrol in treating cancer, including reversing multidrug resistance, are ongoing and may provide valuable insights for future in vivo and clinical studies.
Article
Immunology
Hongli Mao, Jinlin Jia, Jinxiu Sheng, Shanfeng Zhang, Kaida Huang, Hongle Li, Fucheng He
Summary: The study found that Regenerating islet-derived protein 1-alpha (REG1A) was significantly increased in inflamed colorectal tissues of inflammatory bowel disease (IBD) patients, and it could inhibit inflammatory responses, promote cell proliferation, and suppress epithelial apoptosis. IL-6 and IL-22 activated REG1A transcription through the JAK/STAT3 signaling pathway. Overexpression of REG1A in mice alleviated DSS-induced inflammatory injury and maintained intestinal mucosal barrier integrity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Huailin Wang, Yan Fu
Summary: Up-regulation of NR1D1 in ovarian cancer cells inhibits cell proliferation, induces cell cycle arrest and apoptosis, suppresses the JAK/STAT3 signaling pathway through up-regulation of SOCS3, and delays the growth of ovarian cancer cells.
Article
Environmental Sciences
Vimala Karuppaiya, Asaikkutti Annamalai, Shanthi Krishnamurthy, Kannan Soundarapandian
Summary: This study found that the natural substance DCL can inhibit the proliferation and migration of prostate cancer cells by blocking the JAK/STAT3 signaling pathway. The results showed that DCL has significant cytotoxic effects on PC-3 cells and can increase ROS production and apoptotic signals. Additionally, DCL suppresses the expression of proteins that control cell proliferation.
ENVIRONMENTAL TOXICOLOGY
(2023)
Article
Integrative & Complementary Medicine
Shumeng Lin, Jing Wen, Xiao Xu, Jiamin Shi, Wen Zhang, Tiansheng Zheng, Yaqin Hou, Yanfei Zhang, Ziye Li, Kai Wang, Jing Jin, Liduo Yue, Baigenzhin Abay, Ming Li, Qingxi Yue, Lihong Fan
Summary: Amygdalin induces apoptosis of lung cancer cells through multiple mechanisms, including altered expression of apoptosis-related proteins, activation of NF kappa B-1 gene, and inhibition of NF kappa B signaling cascade. These findings reveal the potential of amygdalin as a therapeutic agent for lung cancer.
AMERICAN JOURNAL OF CHINESE MEDICINE
(2022)
Article
Oncology
Gangyin Xie, Linxiao Sun, Yonglin Li, Bicheng Chen, Cheng Wang
Summary: The study demonstrates that periplocin inhibits the proliferation of human pancreatic cancer cells and induces apoptosis by activating the AMPK/mTOR pathway. Additionally, it attenuates cell migration and invasion abilities.
Article
Endocrinology & Metabolism
Songnian Zou, Shouxi Cui, Bin Liang
Summary: This study revealed that overexpressed PLAGL2 and OLFM4 were observed in bladder cancer cells. Silencing of PLAGL2 or OLFM4 suppressed proliferation, promoted apoptosis, and alleviated stemness of bladder cancer cells. PLAGL2 could transcriptionally activate OLFM4 and regulate the STAT3 signaling pathway.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2023)
Article
Plant Sciences
Liru Tian, Chuan Li, Limin Xiang, Jia Zeng, Shuqing Chen, Weimin Guo, Shulin Chen, Yihai Wang, Xiangjiu He, Peiqiang Su, Caixia Xu
Summary: T52, a steroidal saponin extracted from Rohdea fargesii, has been found to possess strong anti-proliferative capabilities in human pharyngeal carcinoma cell lines. In this study, it was demonstrated that T52 also has strong anti-osteosarcoma properties through the inhibition of the STAT3 signaling pathway.
Article
Biotechnology & Applied Microbiology
Yue Xiao, Yanjun Duan, Yongjie Wang, Xiaojia Yin
Summary: The study demonstrated that resveratrol inhibits the growth and promotes apoptosis of CAL-27 oral squamous cell carcinoma cells by regulating the ZNF750/RAC1 signaling pathway. Resveratrol also suppresses malignant progression by modulating the expression of angiogenin, cell adhesion molecules, and vascular markers.
Review
Food Science & Technology
Si-Xia Wu, Ruo-Gu Xiong, Si-Yu Huang, Dan-Dan Zhou, Adila Saimaiti, Cai-Ning Zhao, Ao Shang, Yun-Jian Zhang, Ren-You Gan, Hua-Bin Li
Summary: Cancer is a severe public health problem, and resveratrol, a natural compound with various bioactivities, has been shown to have preventive and therapeutic effects on different types of cancers. This review summarizes the effects and mechanisms of resveratrol in cancer prevention and treatment, providing guidance for the development of functional food, dietary supplements, or auxiliary agents for cancer management.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
(2022)
Review
Biochemistry & Molecular Biology
Alessandro Zucchi, Francesco Claps, Antonio Luigi Pastore, Alessandro Perotti, Andrea Biagini, Luana Sallicandro, Rosaria Gentile, Concetta Caglioti, Federico Palazzetti, Bernard Fioretti
Summary: Bladder cancer is a common urinary system tumor, especially in males. Surgery and intravesical instillations can eliminate it, but recurrences and progression are frequent. Therefore, adjuvant therapy should be considered. Resveratrol has shown potential as an adjuvant therapy for bladder cancer, with anti-proliferative effects at high concentrations and anti-angiogenic action at low concentrations. This review examines the standard therapeutic approach to bladder cancer, preclinical studies on resveratrol in bladder cancer xenotransplantation models, and discusses molecular signals, particularly the STAT3 pathway and angiogenic growth factor modulation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Shixin Chan, Rui Sun, Xucan Tu, Manyu Guo, Qianqian Yuan, Zhen Yu, Zhenglin Wang, Shaocheng Hong, Wei Han, Bingbing Zou, Zeng Li, Huabing Zhang, Wei Chen
Summary: The study demonstrates that rutaecarpine (RUT) can inhibit the proliferation and migration of colorectal cancer cells and induce cell apoptosis by inactivating NF-kappa B/STAT3 signaling pathway. This suggests the potential clinical application of RUT for the treatment of colorectal cancer.
Article
Pharmacology & Pharmacy
Mehmet Berkoz, Ferbal Ozkan-Yilmaz, Arzu Ozluer-Hunt, Miroslaw Krosniak, Omer Turkmen, Duygu Korkmaz, Siddik Keskin
Summary: The study demonstrated that artesunate inhibits cancer cell proliferation by inducing apoptosis, suppressing cell migration, invasion, and colony formation, likely by blocking the STAT3 pathway and related protein expressions. It suggests that artesunate may be a promising candidate for melanoma treatment.
PHARMACOLOGICAL REPORTS
(2021)
Editorial Material
Health Care Sciences & Services
Muhammad Hamza Habib, Sean Marks, Shahzad Raza, Jyoti Malhotra, Mellar P. Davis
JOURNAL OF PALLIATIVE MEDICINE
(2022)
Article
Geriatrics & Gerontology
Nicole M. Armstrong, Hang Wang, E. Jian-Yu, Frank R. Lin, Alison G. Abraham, Pradeep Ramulu, Susan M. Resnick, Qu Tian, Eleanor Simonsick, Alden L. Gross, Jennifer A. Schrack, Luigi Ferrucci, Yuri Agrawal
Summary: This study evaluated the prevalence of individual and multiple sensory impairments among older adults and found that hearing and visual impairments were the most common co-occurring deficits. Combined hearing, vision, and olfactory impairments were more likely to co-occur than expected, especially in older age groups.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2022)
Article
Geriatrics & Gerontology
Yurun Cai, Qu Tian, Alden L. Gross, Hang Wang, Jian-Yu E, Yuri Agrawal, Eleanor M. Simonsick, Luigi Ferrucci, Jennifer A. Schrack
Summary: Components of manual dexterity and strength were the strongest correlates of slow gait and mobility difficulty in mid-to-late life.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2022)
Article
Oncology
M. Palmeri, J. Mehnert, A. W. Silk, S. K. Jabbour, S. Ganesan, P. Popli, G. Riedlinger, R. Stephenson, A. B. de Meritens, A. Leiser, T. Mayer, N. Chan, K. Spencer, E. Girda, J. Malhotra, T. Chan, V Subbiah, R. Groisberg
Summary: This real-world study reinforces the use of TMB as a predictive biomarker, and suggests that clinicians should consider treating TMB-H patients with immunotherapy.
Article
Oncology
Jyoti Malhotra, Lisa E. Paddock, Yong Lin, Sharon R. Pine, Muhammad H. Habib, Antoinette Stroup, Sharon Manne
Summary: This study investigated the impact of race on follow-up care in lung cancer survivors. The results showed significant disparities between non-Hispanic Blacks and non-Hispanic Whites in receipt of surveillance scans and receiving information about the need for follow-up care. Low income, lack of insurance, and financial concerns were identified as significant barriers to follow-up care for cancer survivors.
JOURNAL OF CANCER SURVIVORSHIP
(2023)
Article
Oncology
Ticiana A. Leal, Marina N. Sharifi, Nancy Chan, Robert Wesolowski, Anita A. Turk, Justine Y. Bruce, Ruth M. O'Regan, Jens Eickhoff, Lisa M. Barroilhet, Jyoti Malhotra, Janice Mehnert, Eugenia Girda, Elizabeth Wiley, Natalie Schmitz, Shannon Andrews, Glenn Liu, Kari B. Wisinski
Summary: This study aimed to determine the safety and tolerability of the PARP inhibitor talazoparib with carboplatin and paclitaxel in patients with advanced solid tumors. The results revealed that this combination therapy is associated with significant myelosuppression, and modifying the chemotherapy component may be necessary for further development.
Article
Oncology
Xi-Yang Tang, Yan-Lu Xiong, An-Ping Shi, Ying Sun, Qing Han, Yao Lv, Xian-Gui Shi, Milo Frattini, Jyoti Malhotra, Kai-Fu Zheng, Yu-Jian Liu, Tao Jiang, Nan Ma, Jin-Bo Zhao
Summary: This study finds that FGL1 is highly expressed in LUAD and contributes to the malignant progression of LUAD by promoting cell proliferation. The downregulation of FGL1 inhibits LUAD cell proliferation by regulating MYC-target genes.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Oncology
Gina M. Castellano, Saman Zeeshan, Olga B. Garbuzenko, Hatim E. Sabaawy, Jyoti Malhotra, Tamara Minko, Sharon R. Pine
Summary: CC-115 shows synergy with carboplatin in certain types of late-stage lung squamous cell carcinoma (LUSC) cells, enhancing the effectiveness of chemotherapy by inhibiting the activation of the PI3K/AKT/mTOR signaling pathway.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Respiratory System
Jyoti Malhotra, Brid Ryan, Malini Patel, Nancy Chan, Yanxiang Guo, Joseph Aisner, Salma K. Jabbour, Sharon Pine
Summary: This study found that co-occurring mutations and tumor mutation burden (TMB) may impact response to immunotherapy in STK11-mutated NSCLC patients. Patients with TP53 co-mutation showed improved clinical benefit with immunotherapy, while those with higher TMB had longer progression-free survival with immunotherapy. Co-occurring mutations significantly alter tumor immune landscape and response to immunotherapy in STK11-mutated tumors.
JOURNAL OF THORACIC DISEASE
(2022)
Article
Medicine, General & Internal
Prakash Kulkarni, Atish Mohanty, Supriyo Bhattacharya, Sharad Singhal, Linlin Guo, Sravani Ramisetty, Tamara Mirzapoiazova, Bolot Mambetsariev, Sandeep Mittan, Jyoti Malhotra, Naveen Gupta, Pauline Kim, Razmig Babikian, Swapnil Rajurkar, Shanmuga Subbiah, Tingting Tan, Danny Nguyen, Amartej Merla, Sudarsan Kollimuttathuillam, Tanyanika Phillips, Peter Baik, Bradford Tan, Pankaj Vashi, Sagun Shrestha, Benjamin Leach, Ruchi Garg, Patricia L. Rich, F. Marc Stewart, Evan Pisick, Ravi Salgia
Summary: Drug resistance is a major obstacle in cancer treatment. However, the use of a 'Team Medicine' approach and the development of new therapeutic strategies, such as intermittent therapy, based on eco-evolutionary principles, have shown promising results. Incorporating these strategies into clinical protocols can enhance the precision of personalized medicine.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cell Biology
Vrushank Bhatt, Taijin Lan, Wenping Wang, Jerry Kong, Eduardo Cararo Lopes, Jianming Wang, Khoosheh Khayati, Akash Raju, Michael Rangel, Enrique Lopez, Zhixian Sherrie Hu, Xuefei Luo, Xiaoyang Su, Jyoti Malhotra, Wenwei Hu, Sharon R. Pine, Eileen White, Jessie Yanxiang Guo
Summary: LKB1 and KRAS co-mutations in NSCLC lead to aggressive tumor growth. Inhibition of autophagy and MEK pathway may be a potential therapeutic strategy for NSCLC with LKB1 and KRAS co-mutations.
CELL DEATH & DISEASE
(2023)
Review
Oncology
Jyoti Malhotra, Edward S. Kim
Summary: This review summarizes the recent trials and current status of oncolytic viruses (OVs) for the treatment of lung cancer. While early-phase trials have shown evidence of antiviral immune responses and clinical benefit, the clinical efficacy of OVs in larger trials has not been confirmed. The development of novel combinations with OVs, along with improving tumor specificity and viral load, may be crucial for improving the efficacy of OVs in lung cancer treatment.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Medicine, General & Internal
Sravani Ramisetty, Prakash Kulkarni, Supriyo Bhattacharya, Arin Nam, Sharad S. Singhal, Linlin Guo, Tamara Mirzapoiazova, Bolot Mambetsariev, Sandeep Mittan, Jyoti Malhotra, Evan Pisick, Shanmuga Subbiah, Swapnil Rajurkar, Erminia Massarelli, Ravi Salgia, Atish Mohanty
Summary: Translational research in medicine involves collaboration between scientists from different disciplines to apply knowledge from basic sciences to clinical practice. This approach, known as 'Team Medicine', focuses on addressing specific medical goals through partnership between basic science researchers and clinicians. Using cisplatin resistance in non-small cell lung cancer (NSCLC) as an example, this study demonstrates how a 'Team Science' approach was used to identify a previously approved compound that can alleviate cisplatin resistance in NSCLC. It also highlights the potential of a 'Team Medicine' approach in understanding resistance mechanisms and developing strategies to overcome drug resistance in NSCLC.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Miguel A. Villalona-Calero, Jyoti Malhotra, Vincent Chung, Yan Xing, Stacy W. Gray, Heather Hampel, Stephen Gruber, Kevin McDonnell
Summary: Recent data shows that advanced cancer patients who participate in biomarker/genomically informed early-stage clinical trials benefit clinically. However, most early-stage trials are conducted in academic centers, while the majority of cancer patients in the US are treated in community practices. This article describes efforts at City of Hope Cancer Center to integrate community oncology practices into their academic biomarker/genomic-driven early-stage trial program, aiming to extend the benefits of such trials to community patients. Key initiatives include virtual clinic trials, expansion of clinical trials to regional satellite hubs, and implementation of precision medicine testing programs, which can be used as a model for other institutions.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Ann W. Silk, Biren Saraiya, Roman Groisberg, Nancy Chan, Kristen Spencer, Eugenia Girda, Weichung Shih, Marisa Palmeri, Tracie Saunders, Robert M. Berman, Vlad Coric, Suzie Chen, Andrew Zloza, Joshua Vieth, Janice M. Mehnert, Jyoti Malhotra
Summary: This study aimed to evaluate the safety and tolerability of the combination of troriluzole and nivolumab in patients with advanced solid tumors. The results showed that the combination therapy was safe and well-tolerated, and partial disease stabilization was observed in some patients.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2022)